Table 3.
Baseline characteristics of study sample (n=77)
| Age, mean (sd) | 47 (6.9) |
| Gender, n (%) | |
| Male | 41 (53) |
| Race, n (%) | |
| White | 10 (13) |
| Black | 31 (40) |
| Other | 36 (47) |
| Ethnicity, n (%) | |
| Hispanic | 35 (45) |
| Non-Hispanic | 42 (55) |
| Education, n (%) | |
| High school (partial or completed) | 58 (75) |
| College (partial or completed) | 19 (25) |
| Marriage status, n (%) | |
| Married / living with partner | 34 (44) |
| Widowed / separated / divorced | 22 (29) |
| Single | 21 (27) |
| Employment, n (%) | |
| Employed | 2 (3) |
| Unable to work / unemployed / other, n (%) | 75 (97) |
| Type of Health Insurance, n (%)a | |
| Medicaid | 69 (90) |
| Medicare | 16 (21) |
| Private insurance | 6 (8) |
| Self-reported illicit drug use in the past 30 days, n (%) | |
| Heroin | 20 (26) |
| Cocaine | 22 (29) |
| Crack | 27 (35) |
| Marijuana | 11 (14) |
| Amphetamines | 3 (4) |
| Years of methadone maintenance, median (interquartile range [IQR]) (n=48) | 10 (5–16) |
| Median methadone dose mg, median (IQR) (n=57) | 120 (90–180) |
| Years living with HIV, median (IQR) | 13 (9–17) |
| Years of ARV treatment, n (%) | |
| <1 year | 18 (25) |
| 1 – 5 years | 34 (46) |
| >5 years | 21 (29) |
| Number of pills in regimen, n (%)b | |
| 1 pill | 8 (10) |
| 2 pills | 39 (51) |
| >= 3 pills | 30 (39) |
| Number of doses per day, n (%) | |
| One dose per day | 21 (27) |
| More than one dose a day | 56 (73) |
| Resistance, n (%)c | |
| Not resistant | 62 (81) |
| Resistant | 15 (19) |
| Major mutations, n (%) | |
| NRTId | 5 (6) |
| NNRTIe | 6 (8) |
| PIf | 7 (9) |
| Viral Load (copies/ mL), n (%) (n=73) | |
| <75 | 35 (45) |
| 75 – 400 | 5 (6) |
| 401 – 10,000 | 20 (26) |
| 10,001 – 100,000 | 10 (13) |
| > 100,000 | 3 (4) |
| Absolute CD4+ T cell count cells/mm3, median (IQR) (n=74) | 345 (151–494) |
| Seven-day self-reported adherence , n (%) (n=76) | |
| 100% | 55 (72) |
| < 100% | 21 (28) |
a
Categories not mutually exclusive
b
Participants reporting <3 pills were prescribed combination pills containing 2 or 3 medications
c
At least one major mutation based on the 2008 consensus of the International AIDS Society-USA Drug Resistance Mutations Group; reference #
d
NRTI; nucleoside reverse transcriptase inhibitor
e
NNRTI; non-nucleoside reverse transcriptase inhibitor
f
PI; protease inhibitor